Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Companyâ€™s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
01/26/01	SEK 3.570	+5.00%	5,77,486
30/26/30	SEK 3.400	+3.03%	4,47,904
29/26/29	SEK 3.300	+5.77%	5,74,593
28/26/28	SEK 3.120	+2.30%	1,41,219
25/26/25	SEK 3.050	+9.71%	2,41,509

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 09:30:00 01/10/2026 pm IST			5-day change	1st Jan Change
3.570 ^SEK	+5.00%		+28.42%	+142.86%

26/08	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
23/07	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI

Market Cap	38Cr 3.75Cr 3.33Cr 3.11Cr 2.84Cr 5.34Cr 360.93Cr 5.42Cr 15Cr 183.82Cr 14Cr 14Cr 590.4Cr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	38Cr 3.75Cr 3.33Cr 3.11Cr 2.84Cr 5.34Cr 360.93Cr 5.42Cr 15Cr 183.82Cr 14Cr 14Cr 590.4Cr	EV / Sales 2026 *	4.34x	EV / Sales 2027 *	3.89x
Free-Float	72.16%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	SPRINT	Delayed
Deutsche Boerse AG	5JA1	Delayed
Börse Stuttgart	5JA1	Delayed
Boerse Muenchen	5JA1	Real-time

26/08	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
23/07	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI
26/06	Four stocks have so far today posted new 52-week highs on the Stockholm Stock Exchange	FW
18/06	Nine stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
16/06	Three stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
09/06	Calendar: Tuesday, June 9	FW
08/06	Calendar Tuesday June 9	FW
13/05	Sprint Bioscience Q1 operating loss SEK 14.3 mln	RE
13/05	Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Sprint Bioscience completes strategic evaluation of STK25 program	RE
16/04	Sprint Bioscience and Experimental Drug Development Centre Complete Strategic STK25 Evaluation	CI
14/04	21 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW
10/04	15 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW

Sprint Bioscience AB Share Price

Stocks

SPRINT

SE0006343745

Biotechnology & Medical Research

Valuation: Sprint Bioscience AB

Chart: Sprint Bioscience AB

Latest news: Sprint Bioscience AB

Analysts' recommendations: Sprint Bioscience AB

Press Releases: Sprint Bioscience AB

Quotes and Performance

Price Extremes

Managers and Directors: Sprint Bioscience AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

01/10	Sprint Bioscience Receives Funding from Vinnova	AQ
02/09	Sprint Bioscience (Q2 review): Continued positive progress	AQ
13/08	Sprint Bioscience's Upcoming Conferences and Investor Events	AQ
23/07	Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development	AQ
04/06	Sprint Bioscience (publ) announces that Aktiespararna initiates commissioned research coverage of the company	AQ

1 day	+5.00%
1 week	+28.42%
Current month	+5.00%
1 month	+8.18%
3 months	-16.39%
6 months	+37.31%
Current year	+142.86%

1 week	2.96	3.57
1 month	2.55	3.57
Current year	1.36	4.59
1 year	0.56	4.59
3 years	0.36	4.59
5 years	0.36	5.4
10 years	0.36	40.7

Manager	Title	Age	Since
Johan Emilsson CEO	Chief Executive Officer	42	01/10/2023
Martin Andersson CTO	Chief Tech/Sci/R&D Officer	55	01/01/2009
Jenni Björnulfson DFI	Director of Finance/CFO	55	04/05/2026

Director	Title	Age	Since
Nils Rune Nordlander CHM	Chairman	70	01/01/2010
Fredrik Lehmann BRD	Director/Board Member	50	01/01/2019
Björn Magnus Sjöstrand CHM	Chairman	58	01/01/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPRINT BIOSCIENCE AB	+5.00%	+28.42%	+505.08%	+79.40%	3.75Cr
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	7.44TCr
ARGENX SE	-0.61%	+0.81%	+27.25%	+82.72%	5.93TCr
LONZA GROUP AG	-2.54%	-1.65%	+4.86%	+31.72%	4.71TCr
IQVIA HOLDINGS INC.	-3.02%	-5.20%	+27.94%	+32.51%	4.29TCr
REVOLUTION MEDICINES, INC.	+0.31%	+3.02%	+348.95%	+643.82%	4.41TCr
BEONE MEDICINES AG	-1.96%	-0.33%	+7.04%	+99.46%	4.08TCr
CELLTRION, INC.	+3.32%	+3.49%	+10.10%	+51.23%	3.08TCr
WUXI BIOLOGICS (CAYMAN) INC.	-3.30%	+2.26%	+28.80%	+21.93%	2.93TCr
INSMED INCORPORATED	-4.86%	-10.66%	-26.27%	+330.06%	2.37TCr
Average	-0.35%	+2.37%	+98.31%	+146.70%	3.92TCr
Weighted average by Cap.	-0.39%	-0.32%	+58.48%	+146.04%

	2026 *	2027 *
Net sales	8.68Cr 86.38L 76.72L 71.75L 65.38L 1.23Cr 83Cr 1.25Cr 3.36Cr 42Cr 3.24Cr 3.17Cr 136.04Cr	9.68Cr 96.33L 85.56L 80.02L 72.92L 1.37Cr 93Cr 1.39Cr 3.75Cr 47Cr 3.62Cr 3.54Cr 151.72Cr
Net income	-	-
Net Debt	-	-